Skip to Content

Chronic Lymphocytic Leukaemia – Relapsed Treatment

Click and listen to Professor John Gribben, Barts Cancer Institute, talk about Replase treatment. He talks about the novel agents targeting the B-cell receptor pathway, and how BLC2 inhibitors have now replaced chemoimmunotherapy for relapsed CLL. Agents inhibiting these pathways have unprecedented activity in CLL, especially in high risk patients who previously had such a poor prognosis.

Back to top